Stockscreener 앱 받기
4.59
2.23%
0.10
시간 외 거래:
4.57
-0.02
-0.44%
전일 마감가:
$4.49
열려 있는:
$4.5
하루 거래량:
1.09M
Relative Volume:
1.11
시가총액:
$235.34M
수익:
$676.80M
순이익/손실:
$-8.60M
주가수익비율:
-16.22
EPS:
-0.2829
순현금흐름:
$135.40M
1주 성능:
-5.17%
1개월 성능:
-38.80%
6개월 성능:
-57.62%
1년 성능:
-47.96%
1일 변동 폭
$4.45
$4.67
1주일 범위
$4.36
$4.73
52주 변동 폭
$4.36
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
4.59 | 233.29M | 676.80M | -8.60M | 135.40M | -0.2829 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Emergent Biosolutions Inc. (NYSE:EBS) Given Average Rating of "Hold" by Analysts - marketbeat.com
Q2 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Q4 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Q1 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Emergent BioSolutions Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
American Century group reports 5.4% Emergent BioSolutions (EBS) ownership on Schedule 13G - Stock Titan
Emergent Biosolutions (EBS) Earnings Date and Reports 2026 $EBS - MarketBeat
Levi & Korsinsky Notifies Investors of Pending - GlobeNewswire
Emergent Biosolutions (NYSE:EBS) Rating Increased to Hold at Zacks Research - marketbeat.com
Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript - AOL.com
EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS) - Business Wire
Emergent BioSolutions (EBS) EVP Stephanie Duatschek details stock and option holdings - Stock Titan
Trade Desk, Papa John's, Emergent BioSolutions Hit 52-Week Lows as Weak Results Trigger Analyst Downgrades - finance.biggo.com
EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions - PR Newswire
EMERGENT BIOSOLUTIONS INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $10 FROM $12 - webull.com
Why Did TTD, PZZA, EBS Stocks Plummet To 52 Week Lows? - Stocktwits
Emergent BioSolutions cuts FY2026 revenue forec... - Pluang
Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS) - PR Newswire
H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
H.C. Wainwright cuts Emergent BioSolutions stock price target on revenue outlook - Investing.com Nigeria
Emergent Biosolutions (NYSE:EBS) Given New $10.00 Price Target at HC Wainwright - marketbeat.com
EBS Maintained by HC Wainwright & Co. -- Price Target Lowered to $10 - GuruFocus
Emergent BioSolutions Inc (EBS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Emergent BioSolutions (EBS) Stock Sinks As NARCAN Impairment Deepens Losses - Sahm
Emergent BioSolutions Inc (EBS) Stock News Today - TradingKey
Emergent Biosolutions Q2 Earnings Call Highlights - MarketBeat
Watch Out on Emergent BioSolutions Inc.: Strong Operational Recovery Tempered by Commercial Headwinds and Strategic Reset - Kalkine
Despite Hitting US$5.31, Emergent BioSolutions Insiders Still Sold Too Soon - moomoo.com
Pacer Advisors Inc. Purchases Shares of 416,191 Emergent Biosolutions Inc. $EBS - MarketBeat
Emergent BioSolutions Inc. (EBS): Investor Outlook Reveals 125.99% Potential Upside - DirectorsTalk Interviews
Dimensional Fund Advisors LP Has $22.88 Million Position in Emergent Biosolutions Inc. $EBS - MarketBeat
Emergent BioSolutions Shares Plunge After 2026 Guidance Cut, Restructuring - moomoo.com
Emergent BioSolutions Announces Restructuring Amid Turnaround Efforts - The Globe and Mail
Emergent BioSolutions laying off dozens, shedding real estate as Narcan competition strains profits - The Business Journals
Emergent BioSolutions | 10-Q: Q2 2026 Earnings Report - moomoo.com
Emergent Bio stock slips despite Q2 beat (EBS:NYSE) - Seeking Alpha
Emergent BioSolutions Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Emergent BioSolutions Inc. 2026: Revenue $234.3M, EPS ($3.49) — 10-Q Summary - TradingView
Emergent BioSolutions (NYSE: EBS) posts Q2 loss, plans cost-cutting - Stock Titan
Emergent Q2 2026 slides: strong quarter, but guidance cut sparks selloff - Investing.com
Emergent Biosolutions (NYSE:EBS) Announces Quarterly Earnings Results - MarketBeat
Earnings call transcript: Emergent BioSolutions Q2 2026 revenue tops guidance - Investing.com
Emergent BioSolutions Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is Emergent BioSolutions Inc (EBS) Overvalued After Q2 Earnings - GuruFocus
Emergent Q2 2026 slides: MCM strength offset by naloxone pressure - Investing.com
EBS: Strong Q2 driven by MCM, but naloxone competition prompts lower guidance and restructuring - TradingView
Emergent BioSolutions Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:EBS) 2026-08-05 - Seeking Alpha
Emergent Q2 2026 earnings: MCM growth contrasts with NARCAN impairment - TradingKey
Q2 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Emergent BioSolutions Reports Second Quarter 2026 Financial Results - The Manila Times
Emergent Biosolutions: Q2 Earnings Snapshot - Yahoo Finance
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
5.15%
자본화:
|
볼륨(24시간):